# INTERPRETATION_CHECKPOINT.md

## Document Information

**Document:** INTERPRETATION_CHECKPOINT.md
**Project:** 12-Gene Gastric Cancer Signature — Part 2: Modernized Biomarker Discovery Framework
**Checkpoint:** Interpretation Checkpoint (end of Phase E, per IMPLEMENTATION_MASTER_PLAN.md §5/§8)
**Covers:** Module 12 (Scientific Interpretation), Module 13 (Evidence Integration / Interpretation Outputs) — all LOCKED; completes IDS-005 in full
**Prepared by:** Coding Agent (Claude), for Strategist AI review
**Status:** DRAFT — awaiting Strategist Review and Project Coordinator confirmation before Phase F (Clinical Translation, IDS-006) begins

---

## 1. Purpose

Per `IMPLEMENTATION_MASTER_PLAN.md` §8, a checkpoint verifies, across all modules in the completed phase: module completion; contract compliance; artifact integrity; lineage preservation; downstream readiness. This document assembles that evidence for Modules 12–13 (Phase E — Interpretability), mirroring the structure used for the Discovery, Modeling, and Validation Checkpoints. Execution shall not proceed into Phase F — Clinical Translation until this checkpoint passes.

This document introduces no new implementation, no new governance decision, and reinterprets nothing already LOCKED. It is a synthesis-only artifact.

---

## 2. Module Completion

| Module | Responsibility | Status | LOCK date |
|---|---|---|---|
| Module 12 | Scientific Interpretation (`run_interpretation()`, Interpretation Object, Interpretation Evidence) | LOCKED | 2026-06-29 |
| Module 13 | Evidence Integration (`run_evidence_integration()`, Evidence Integration Object, Interpretation Package) | LOCKED | 2026-06-29 |

Both modules have a complete, LOCKED `Execution/Module_1X/` history (`Prompt.md`, `Artifacts.md`, `Execution_Log.md`, `Review.md`, `LOCK.md`), each independently Strategist-reviewed and Project-Coordinator-confirmed.

**Workflow note:** Modules 12 and 13 continued the "Strategist-direct" review workflow established at Module 10 (Project Coordinator works with the Strategist directly, returns finalized `Review.md` + console output). Additionally, starting at Module 12, packaging changed to delivering **only the new files each module introduces**, rather than the full repository — both changes introduced no governance or traceability gap; `Execution_Log.md` for both modules continued to be populated from real `devtools::test()`/`devtools::check()` console output.

**Two Consistency Check clarifications** were recorded during this phase, both extending (not conflicting with) locked architecture:

1. **Module 12:** as the first module of a new domain (IDS-005), `metadata$framework_layer = "interpretability"` (new layer) and `metadata$artifact_role = "interpretation_evidence"` were introduced; default consumer `"interpretation_package"` (naming Module 13's responsibility directly).
2. **Module 13:** `metadata$artifact_role = "interpretation_package"` (sharing Module 12's `"interpretability"` layer); default consumer `"clinical_translation"` (naming Phase F directly, per `IMPLEMENTATION_MASTER_PLAN.md`).

---

## 3. Contract Compliance

Both modules consume Module 02's Framework Contracts and their immediately-upstream module exactly as LOCKED — zero modifications anywhere in Phase E.

| Module | Framework artifact produced | `artifact_role` | Upstream artifact consumed (read-only) |
|---|---|---|---|
| Module 12 | Interpretation Evidence | `"interpretation_evidence"` | Validated Candidate only (Module 11) |
| Module 13 | Interpretation Package | `"interpretation_package"` | Interpretation Evidence only (Module 12) |

**Verification:** `contract_type` remained exactly `"artifact"` in both artifacts — confirmed by dedicated tests in each module (e.g. `test-evidence-integration.R`: "create_interpretation_package introduces no new Framework Contract type"). This is the **first new `framework_layer` introduced after completion of Phase D** (since `"validation_benchmark"`), confirming the layer-naming mechanism extends cleanly across IDS domain boundaries, not just within one IDS. Each module strictly narrowed its consumption to exactly one upstream artifact type, continuing the one-hop consumption rule the Strategist explicitly endorsed at the Validation Checkpoint.

No new contract schema, contract type, or object model was introduced anywhere in Phase E.

---

## 4. Artifact Integrity

| Principle | Module(s) | Evidence |
|---|---|---|
| Workflow/Executor/Object/Evidence separation | 12, 13 | Each module implements the identical structural pattern established in Modules 09–11: `create_*_object()` → `run_*()` → `list(*_object, *_artifact)`. |
| Generic Implementation Principle (no real methodology) | 12, 13 | `.default_generic_interpreter()` and `.default_generic_integrator()` each return only a single `structural_check` component, with `details` text explicitly disclaiming pathway/enrichment/SHAP/feature-importance/biological methodology (Module 12) and evidence-synthesis/biological/clinical/publication methodology (Module 13) — verified directly in tests. |
| Callback extensibility | 12, 13 | `interpreter`/`integrator` parameters, defaulting to `NULL` → internal generic default, mirror the `trainer`/`validator`/`benchmarker`/`selector` pattern exactly. |
| Read-only upstream consumption | 12, 13 | Verified directly: Validated Candidate unchanged after Module 12; Interpretation Evidence unchanged after Module 13 — via `identical()` against independent copies/originals. |
| Multiple independent components (no opaque collapse) | 12, 13 | Each module's workflow function tested with 3 named components, returned intact and distinguishable. |
| Forbidden-content guards | 12, 13 | Module 12's Interpretation Evidence rejects `evidence_integration`, `interpretation_package`, `clinical_translation`, `publication_ready_interpretation`; Module 13's Interpretation Package rejects `biological_reasoning`, `clinical_interpretation`, `therapeutic_recommendation`, `publication_ready_discussion`, `scientific_conclusions` — both at construction and validation time, tested explicitly. |
| Anti-duplication via direct reuse | 12, 13 | Module 12 calls Module 11's exported `validate_validated_candidate()` directly; Module 13 calls Module 12's exported `validate_interpretation_evidence()` directly — neither reimplements upstream validation logic. |

---

## 5. Lineage Preservation — End-to-End Trace, Module 12 → 13

The following trace extends the Discovery, Modeling, and Validation Checkpoints' traces, completing the chain from the original Discovery artifact through to the final IDS-005 output:

```
(...continued from Validation Checkpoint: validated_candidate,
 embedding candidate_selection_object, produced by Module 11...)
        |
        v
Module 12                                          Module 13
----------                                          ----------
create_interpretation_object(validated_candidate)
        |
        v
[interpretation_object]
        |
run_interpretation(interpretation_object)
        |
        v
[interpretation_object (updated)] -> create_interpretation_evidence()
        |
        v
[interpretation_evidence: artifact_contract,
 framework_layer = "interpretability",
 artifact_role = "interpretation_evidence",
 embeds interpretation_object]
        |
        +-----------------------------------------> create_evidence_integration_object(interpretation_evidence)
                                                              |
                                                              v
                                                      [evidence_integration_object]
                                                              |
                                                      run_evidence_integration(evidence_integration_object)
                                                              |
                                                              v
                                                      [evidence_integration_object (updated)] -> create_interpretation_package()
                                                              |
                                                              v
                                                      [interpretation_package: artifact_contract,
                                                       framework_layer = "interpretability",
                                                       artifact_role = "interpretation_package",
                                                       consumer = "clinical_translation",
                                                       embeds evidence_integration_object]
                                                              |
                                                              v
                                              ready for Phase F (Clinical Translation, IDS-006)
```

**Key lineage guarantees confirmed by this trace:**
- The original Module 04 Discovery artifact (`metadata$framework_layer = "processing"`) remains traceable, byte-for-byte unchanged, through the **complete 11-module chain**: `model_contract` → `model_object` → `training_object` → `model_candidate`/`modeling_evidence` → `validation_object` → `validation_evidence` → `benchmark_object` → `benchmark_evidence` → `candidate_selection_object` → `validated_candidate` → `interpretation_object` → **`interpretation_evidence`** → `evidence_integration_object` → **`interpretation_package`**.
- This is confirmed directly by `test-evidence-integration.R::"create_interpretation_package integrates end-to-end with Modules 06-12 construction"`, which asserts `identical()` between the original Discovery artifact and the one reachable by drilling through `interpretation_package`'s full embedded lineage.
- No step in Phase E duplicates upstream validation/contract logic (Section 4).
- One-hop consumption held throughout: Module 12 never directly touches Benchmark/Validation Evidence; Module 13 never directly touches Validated Candidate, Benchmark Evidence, or Validation Evidence.

---

## 6. API Stability Inventory

| Module | Exported function | Signature | Returns |
|---|---|---|---|
| 12 | `create_interpretation_object()` | `(validated_candidate, metadata = list())` | `interpretation_object` |
| 12 | `validate_interpretation_object()` | `(x)` | invisible `TRUE` or error |
| 12 | `run_interpretation()` | `(interpretation_object, interpreter = NULL, ...)` | `list(interpretation_object, interpretation_evidence)` |
| 12 | `create_interpretation_evidence()` | `(interpretation_object, producer = NULL, consumer = "interpretation_package", metadata = list())` | `interpretation_evidence` |
| 12 | `validate_interpretation_evidence()` | `(x)` | invisible `TRUE` or error |
| 12 | `print.interpretation_object()` / `print.interpretation_evidence()` | S3 only | invisible `x` |
| 13 | `create_evidence_integration_object()` | `(interpretation_evidence, metadata = list())` | `evidence_integration_object` |
| 13 | `validate_evidence_integration_object()` | `(x)` | invisible `TRUE` or error |
| 13 | `run_evidence_integration()` | `(evidence_integration_object, integrator = NULL, ...)` | `list(evidence_integration_object, interpretation_package)` |
| 13 | `create_interpretation_package()` | `(evidence_integration_object, producer = NULL, consumer = "clinical_translation", metadata = list())` | `interpretation_package` |
| 13 | `validate_interpretation_package()` | `(x)` | invisible `TRUE` or error |
| 13 | `print.evidence_integration_object()` / `print.interpretation_package()` | S3 only | invisible `x` |

**Total: 14 exported public symbols across the Interpretability domain (Modules 12–13)** — 10 via `export()`, 4 S3 print methods via `S3method()` registration only. Zero renames, zero semantic changes, zero breaking changes since each function's respective LOCK.

The framework now exposes **63 stable public API symbols at the completion of Phase E** (49 from Phases B–D, per the Validation Checkpoint, + 14 from Phase E).

---

## 7. Test Coverage Summary

| Test file | Module | Assertions (PASS) |
|---|---|---|
| `test-interpretation.R` | 12 | 61 |
| `test-evidence-integration.R` | 13 | 62 |
| **Interpretability domain subtotal** | | **123** |
| Full package suite (Modules 01–13 combined) | — | **654** |

All 654 assertions pass with `[ FAIL 0 | WARN 0 | SKIP 0 ]`, confirmed at each module's local execution and re-confirmed cumulatively at every subsequent module.

`devtools::check()` at every module in this phase: **0 errors, 0 warnings**, 1 note (system-clock-related, accepted as expected at this project stage — consistent across Modules 02–13).

No pathway analysis, enrichment analysis, SHAP, feature importance, biological reasoning, evidence synthesis, biological/clinical integration, or publication formatting is tested anywhere in the Interpretability domain, consistent with the Generic Implementation Principle carried through Phase E.

No test-fixture or implementation issues required correction in this phase.

---

## 8. Downstream Compatibility

The Interpretability domain's output, as implemented by Module 13, is ready for Phase F:

- Exactly one Interpretation Package is produced per Evidence Integration Object, a stable `artifact_contract`-based Framework artifact (`contract_type == "artifact"`, `metadata$artifact_role == "interpretation_package"`, `consumer == "clinical_translation"` by default) — the single, terminal output of IDS-005.
- Interpretation Package structurally forbids biological reasoning, clinical interpretation, therapeutic recommendation, publication-ready discussion, and scientific conclusions — meaning Phase F (Clinical Translation) is the **first** domain in the entire framework explicitly authorized to introduce clinical interpretation and recommendation, with a clean, unambiguous starting boundary (mirroring how Phase E was the first domain authorized for scientific interpretation, per the Validation Checkpoint).
- The `trainer`/`validator`/`benchmarker`/`selector`/`interpreter`/`integrator` callback pattern (Modules 07, 09–13) has now become the established Coding Phase execution pattern for how Phase F may eventually inject real clinical-translation methodology without requiring rework of any locked module.
- No real pathway/enrichment/SHAP/biological/clinical methodology has been "locked in" anywhere in Modules 12–13 — the entire Interpretability domain remains generic scaffolding, ready for real interpretation methodology to be introduced via callbacks in future, additive work.
- The `metadata$framework_layer` mechanism has now been demonstrated across **three** domain boundaries (`"discovery"`/`"processing"` → `"modeling"` → `"validation_benchmark"` → `"interpretability"`), confirming it scales as a general per-domain naming convention, not just a per-module one.

---

## 9. Open Items / Carried-Forward Notes

- **Workflow changes absorbed cleanly:** the "Strategist-direct" review workflow (since Module 10) and the "new-files-only" packaging convention (since Module 12) introduced no governance or execution-history gaps across four consecutive modules now (10, 11, 12, 13).
- **Carried over from prior Checkpoints:** IDS-002's Discovery Candidate/Evidence taxonomy remains uninstantiated as a distinct pair (Module 04 produces one generic artifact) — unrelated to, and unaffected by, IDS-003/004/005's now-complete artifact taxonomies.
- **Carried over from Module 09:** a future (non-blocking) documentation enhancement may explicitly document `trained_model` as an intentionally opaque implementation object — still deferred, not required.
- **No new open items were raised in Module 12 or 13's reviews** beyond standard "no revisions required."

---

## 10. Checkpoint Self-Assessment (Coding Agent, pre-Strategist)

- [x] Module completion — Modules 12, 13 both LOCKED with complete execution history; IDS-005 fully complete.
- [x] Contract compliance — Module 02 contracts and each module's immediately-upstream artifact used unmodified throughout; first new `framework_layer` since Phase D introduced cleanly.
- [x] Artifact integrity — Workflow/Executor/Object/Evidence separation, generic-only defaults, callback extensibility, read-only consumption, multiple-component support, and forbidden-content guards all verified in tests across both modules.
- [x] Lineage preservation — End-to-end trace (Section 5), continuous from Module 04 through Module 13 (11 modules deep), confirmed by automated tests.
- [x] Downstream readiness — Output boundary is minimal, stable, and explicitly designed to receive Phase F's real clinical-translation methodology without Phase B–E rework; 14 new public APIs frozen with zero breaking changes.

This self-assessment does not substitute for Strategist Review. Per `IMPLEMENTATION_MASTER_PLAN.md` §8, execution shall not proceed into Phase F — Clinical Translation until this checkpoint formally passes.

---

## 11. Requested Strategist Actions

1. Review Sections 2–9 above against the underlying `Execution/Module_12/`, `Module_13/` records for accuracy.
2. Confirm or challenge the Section 10 self-assessment against each of the five checkpoint criteria.
3. Confirm that the two Consistency Check clarifications across Modules 12–13 remain architecturally sound, in particular the introduction of the first new `metadata$framework_layer` value since Phase D.
4. Confirm the combined "Strategist-direct review" + "new-files-only packaging" workflow has not introduced any cumulative drift across four consecutive modules (10–13).
5. Issue an explicit **Interpretation Checkpoint** verdict: **PASS** (proceed to Module 14 / IDS-006 Discussion) or **REVISION REQUIRED**.
6. Flag any cross-module concern only visible at the full-phase level — e.g., whether Phase F (the first domain authorized for clinical interpretation/recommendation) should anticipate any structural precedent from how Phase E was first authorized for scientific interpretation, or whether IDS-006's two modules (Clinical Translation, Clinical Outputs) should expect the same Workflow/Executor/Object/Evidence pattern verbatim.

---

End of INTERPRETATION_CHECKPOINT.md (draft, for Strategist Review).

---
---

# INTERPRETATION_CHECKPOINT_REVIEW.md

**Checkpoint:** Interpretation Checkpoint (Phase E Integration)
**Reviewer:** Strategist AI (ChatGPT)
**Status:** PASS

---

## Overall Verdict

**PASS.** A high-quality checkpoint. No governance conflict, IDS conflict, architectural drift, API inconsistency, artifact inconsistency, lineage issue, or phase-boundary issue was found. Only two editorial improvements, neither a revision.

## Section-by-Section Review

All ten sections (Purpose, Module Completion, Contract Compliance, Artifact Integrity, Lineage Preservation, API Stability Inventory, Test Coverage, Downstream Compatibility, Open Items, Self-Assessment) — **PASS**, each confirmed against the underlying evidence rather than accepted on the checklist alone.

**Highlights called out by the Strategist:**
- **Contract Compliance:** the one-hop chain (Validated Candidate → Interpretation Evidence → Interpretation Package) is held precisely, with no extraneous artifact, no new `contract_type`, and no modification to Module 02 — assessed as a particularly strong point.
- **Lineage Preservation:** assessed as the strongest section — it doesn't merely assert "lineage preserved," it demonstrates the full chain (Discovery → ... → Interpretation Package) with `framework_layer`, `artifact_role`, and embedded lineage as concrete evidence.
- **Downstream Compatibility:** the framing of Phase F as "the first domain authorized [for clinical interpretation/recommendation]" cleanly establishes the boundary.

## Editorial Improvements (not revisions — applied)

1. **Section 3:** "first new framework_layer since Phase D" → "first new framework_layer introduced after completion of Phase D" (more natural phrasing; no content change).
2. **Section 8:** "callback pattern is now a six-instance precedent" → "callback pattern has now become the established Coding Phase execution pattern" (by Module 13, this is no longer merely a precedent — it is the Coding Phase's official execution pattern; no content change).

Both have been applied to `INTERPRETATION_CHECKPOINT.md` above.

---

## Responses to Requested Strategist Actions

### Action 1 — Review accuracy

**Confirmed.** No inconsistency identified.

### Action 2 — Checkpoint criteria

**Confirmed.** All five criteria are satisfied.

### Action 3 — `framework_layer` introduction

**Confirmed.** The progression `processing → modeling → validation_benchmark → interpretability` shows `framework_layer` has matured into a domain taxonomy. **Not recommended for immediate Governance inclusion** — it should be synthesized at **Coding Framework Integration** after Module 15, per the already-locked workflow.

### Action 4 — Strategist-direct review + new-files-only packaging

**Confirmed.** After Modules 10, 11, 12, and 13, this workflow has demonstrated: no loss of traceability; no loss of governance; no loss of execution history; a significant reduction in review overhead. Treated as an **Operational SOP** — no further Governance update required.

### Action 5 — Interpretation Checkpoint Verdict

**PASS.** Proceed to Module 14 Discussion (IDS-006, Clinical Translation).

### Action 6 — Structural concern for Phase F?

**An observation, not a concern.** Phase E demonstrated `Scientific Interpretation → Interpretation Package`; Phase F will be `Clinical Translation → Clinical Package`. **Recommendation: Modules 14 and 15 should continue the identical architectural template** (Workflow → Executor → Implementation Object → Framework Artifact), with no shortcuts. This keeps Modules 09–15 fully symmetric, simplifies Coding Framework Integration after Module 15, and gives the framework one unified execution architecture. This is an **architectural recommendation, not a governance decision**.

---

## Final Verdict

**Interpretation Checkpoint: PASS**

No implementation revision required. No governance revision required. No architecture revision required. Only the two editorial improvements above, both applied.

---

## Strategist Recommendation

**APPROVED**

- ✅ Module 12: LOCKED
- ✅ Module 13: LOCKED
- ✅ IDS-005: Completed
- ✅ Phase E (Interpretability): Completed
- ✅ Interpretation Checkpoint: **PASSED**

Per `IMPLEMENTATION_MASTER_PLAN`, the project is **approved to proceed to Phase F — Clinical Translation**, beginning with **Module 14 Discussion**.
